

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

\*FHK- Florida Healthy Kids

# Hyaluronan Injections

CG-DRUG-29  
DRUG.00017

Overrides
Non Approvable

***\*Washington Medicaid - See State Specific Mandate below***

Medications
Durolane (sodium hyaluronate)
Euflexxa (sodium hyaluronate)
Gel-One (Cross-linked sodium hyaluronate)
Gelsyn-3 (sodium hyaluronate)
GenVisc 850 (sodium hyaluronate)
Hyalgan (sodium hyaluronate), all dose forms
Hymovis (non-crosslink sodium hyaluronate)
Monovisc (sodium hyaluronate)
Orthovisc (hyaluronic acid)
Supartz FX (sodium hyaluronate)
Supartz (sodium hyaluronate)
Synvisc (hylan G-F 20 [polymer of A and B])
Synvisc-One (hylan G-F 20 [polymer of A and B])
Trivisc (sodium hyaluronate)
Visco-3 (sodium hyaluronate)

- I. Intra-articular injections of hyaluronan for all joints including, but not limited to, the knee, ankle, shoulder, hip, temporomandibular joint, or thumb **may not be approved.**

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

\*FHK- Florida Healthy Kids

State Specific Mandates		
State Name	Date effective	Mandate details (including specific bill if applicable)
Washington Medicaid – Number and coverage topic: 20131114A – Hyaluronic Acid/ Viscosupplementation		<p>Restricted to the treatment of pain associated with osteoarthritis of the knee (OA), when all the following conditions are met:</p> <ol style="list-style-type: none"> <li>1. Restricted to patients who have a <u>documented medical contraindication</u> to other forms of non-surgical care including <b>all</b> of the following: <ul style="list-style-type: none"> <li>• NSAIDS (for example, GI bleed, renal disease)</li> <li>• <b>AND</b> corticosteroid injections (allowed contraindications include: local cellulitis, septic arthritis, acute fracture, bacteremia, joint prosthesis, achilles or patella tendinopathies, history of allergy or anaphylaxis to injectable pharmaceuticals or constituents)</li> <li>• <b>AND</b> physical therapy/exercise (for example, recent acute cardiac event, unstable angina, pulmonary infarction)</li> </ul> </li> <li>2. Limited to two courses per year</li> <li>3. Documented evidence of clinical benefit in terms of pain <b>AND</b> function from prior course of treatment is required for subsequent treatment courses.</li> </ol> <p>Treatment of temporomandibular joint (TMJ) disorders is an excluded benefit.</p>

**Key References:**

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.  
CRX-ALL-0298-18

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

\*FHK- Florida Healthy Kids

1. American Academy of Orthopedic Surgeons. Clinical practice guideline. Treatment of osteoarthritis of the knee. May 2013. Available at: <http://www.aaos.org/research/guidelines/TreatmentofOsteoarthritisoftheKneeGuideline.pdf>. Accessed on December 6, 2017.
2. American Medical Society for Sports Medicine. Scientific statement concerning viscosupplementation injections for knee osteoarthritis: importance for individual patient outcomes. 2016. Available at: <http://bjsm.bmj.com/content/50/2/84>. Accessed on February 1, 2018.
3. Bellamy N, Campbell J, Robinson V, et al. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. 2006; (2):CD005321.
4. Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012; 64(4):465-474. Available at: [http://www.rheumatology.org/practice/clinical/guidelines/ACR\\_2012\\_OA\\_Guidelines.pdf#toolbar=1&pagemode=bookmarks](http://www.rheumatology.org/practice/clinical/guidelines/ACR_2012_OA_Guidelines.pdf#toolbar=1&pagemode=bookmarks). Accessed on December 6, 2017.
5. Jüni P, Hari R, Rutjes AWS, et al. Joint corticosteroid injection for knee osteoarthritis. Cochrane Database Syst Rev. 2015(10):CD005328.
6. National Institute of Dental and Craniofacial Research of the National Institutes of Health. TMJ (Temporomandibular Joint and Muscle Disorders). Available at: <http://www.nidcr.nih.gov/OralHealth/Topics/TMJ/>. Accessed on December 6, 2017.
7. Osteoarthritis Research Society International. Guidelines for the non-surgical management of knee osteoarthritis. 2014. Available at: [https://www.oarsi.org/sites/default/files/docs/2014/non\\_surgical\\_treatment\\_of\\_knee\\_oa\\_march\\_2014.pdf](https://www.oarsi.org/sites/default/files/docs/2014/non_surgical_treatment_of_knee_oa_march_2014.pdf) Accessed on February 1, 2018.
8. Witteveen AG, Hofstad CJ, Kerkhoffs GM. Hyaluronic acid and other conservative treatment options for osteoarthritis of the ankle. Cochrane Database Syst Rev. 2015(10):CD010643.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.